NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2 NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2 Aarhus, Denmark, 18 November 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated...

NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2 NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2 Aarhus, Denmark, 18 November 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated...

NMD Pharma expands its US presence PRESS RELEASE NMD Pharma expands its US presence Creates US subsidiary and increases US R&D and staff recruitment activity Aarhus, Denmark, 3 May 2022 – NMD Pharma A/S, a clinical stage biotech...

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech...